Skip to content

The Association Between Glycemic Metrics and Cardiovascular Markers in Patients With Type 1 Diabetes.

The Association Between Glycemic Metrics and Cardiovascular Markers in Patients With Type 1 Diabetes.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06978387
Enrollment
90
Registered
2025-05-18
Start date
2025-01-01
Completion date
2026-12-01
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Brief summary

In this cross-sectioanl study, 90 patients aged \>12 years old with T1DM who are on MiniMed 780G system will be included.The investigators aim to assesse the association of patients' adherence to Mediterranean diet (MD) with CGM and insulin metrics, as well as anthropometric measurements, BMI, lipid levels and blood pressure.Moreover, markers of endothelial, cardiovascular and liver function will be also assessed and associated with the use of Minimed 780G and the adherence to MD.

Detailed description

This cross-sectional study will include 90 participants, children adolescents and young adults (12\> years old) with T1D that are on MiniMed 780G system. Participants will be evaluated for adherence to Meditteranean Diet (MD) with PREDIMED questionnaire. HbA1c, CGM and Insulin Metrics, anthropometric measurements, blood pressure and lipid leves will be aso evalutaed. Markers of endothelial cardiovascular and liver function will also be assessed.

Interventions

patients aged \>12 years old with T1DM who are on MiniMed 780G

Sponsors

Attikon Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
12 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of type 1 diabetes \>1 year prior to consent date. Diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required. 2. HbA1c \< 12.5% 3. Age \>7years at the initiation of the system 4. Patients with Minimed 780G 5. History of 3 clinic visits in the last year

Exclusion criteria

Diabetic Ketoacidosis in the 6 months prior to screening visits

Design outcomes

Primary

MeasureTime frameDescription
Time in RangeBaselineAssessment of time in range
Time below rangeBaselineAssessment of time below range
Time above rangeBaselineAssessment of time above range
Basal Insulin doseBaselineAssessment of basal insulin doses
Correction Insulin doseBaselineAssessment of correction insulin dose
Pulse wave velocityBaselineAssessment of pulse wave velocity
Endothelial glycocalyxBaselineAssessemnet of the thickness of endothelial glycocalyx
Global longitudinal strainBaselineAssessment of global longitudinal strain.
E scoreBaselineAssessement of E score and CAP score.
Assessment of CAP scoreBaselineCAP score
MED dietBaselineAssesment of Adherence to MED diet
Fat massBaselineAssessment of fat mass
Lean MassBaselineAssessment of lean mass

Countries

Greece

Contacts

PRINCIPAL_INVESTIGATORVaia Lambadiari

Attikon General University Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 15, 2026